Lifecore Biomedical, Inc. (LFCR)
After hours:
| Previous Close | 6.87 |
| Open | 6.89 |
| Bid | 6.65 x 100 |
| Ask | 6.70 x 300 |
| Day's Range | 6.60 - 6.89 |
| 52 Week Range | 4.13 - 11.46 |
| Volume | |
| Avg. Volume | 198,390 |
| Market Cap | 203.137M |
| Beta (5Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | May 09, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
Insider MonkeyHidden Gems: Unveiling the 10 Stocks on Hedge Funds’ Radar
In this article we are going to reveal the names of 10 stocks that are on hedge funds’ radar. The US market sustained strong performance in the first quarter of 2024 as the S&P Index increased by 10.6%, continuing its momentum from the previous quarter. There is a prevailing optimism in the market regarding a […]
Insider MonkeyWhat Made White Falcon Hold Lifecore Biomedical (LFCR)?
White Falcon Capital Management, an investment fund manager, released its first quarter 2024 investor letter. A copy of the same can be downloaded here. The portfolio achieved a satisfactory result on an absolute basis during the quarter. In the first quarter, the fund was up 8.7% compared to a 12.8% return for the S&P 500 […]
GlobeNewswireLifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarter
